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LETTERS TO THE EDITORDEFICIENCY IN COMPARISON
OF DATA BETWEEN
MECHANICALVALVE STUDIES
To the Editor:
After reading the e-publication of
the November 2010 article by Chan
and colleagues,1 we noted compara-
tive data from previously published
studies cited or incompletely cited
when data were available. Three ge-
neric and 2 specific issues should be
addressed in the interpretation of the
data presented.
First, the guideline document is that
of their reference 14 by Akins and as-
sociates.2 This document, however,
does not differentiate major or minor
embolic events. The guidelines re-
quire reporting of all events.
Second, the term major thrombo-
embolism is not defined in the article
by Chan and colleagues,1 nor is it
used according to the referenced
guideline document.2 What does the
term major thromboembolic events
mean? Not having these events de-
fined creates confusion when compar-
isons are made with other articles, as
in Chan and colleagues’ Table 3.1
Third, a thorough review of the
article by the authors was not com-
pleted, because their references 19
and 24 are identical and calculations
of valve-related events are incom-
pletely reported.
Specific issues of concern are com-
parisons with other publications3,4
noted in their Table 3. Chan and
colleagues1 compare major thrombo-
embolic events with those reported byThe Editor welcomes submissions for possible publica-
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The Journalour group inTheJournal ofHeartValve
Disease in 20043 for the ATS Medical
valve (ATSMedical, Inc, Minneapolis,
Minn). Table 3 in their article1 cites
a ‘‘major thromboembolic’’ rate for
ATS Medical aortic valve replacement
(AVR) of 1.6%/patient-year and a rate
for the ATS Medical mitral valve re-
placement (MVR) of 2.2%/patient-
year; however, in our report, major
events (permanent neurologic and
peripheral embolic events) were
0.7%/patient-year for AVR and
0.4%/patient-year, as shown our Ta-
ble V.3 Other events reported were
transient and minor (minor transient
thromboembolic events 12 of 16 for
AVR and 6 of 8 for MVR), adhering
to guideline recommendations. Thus
the total thromboembolic events, not
the major thromboembolic events,
were 1.6%/patient-year and 2.2%/
patient-year for AVR and MVR,
respectively.
Freedom from valve-related mor-
tality was not noted for the ATS
valve in Table 3 of Chan and col-
leagues,1 but in the article cited,3
valve-related mortality was clearly
reported as 0.8% per year for both
aortic and mitral positions. Freedoms
from valve related-deaths over 5
years were 96% for the ATS Medical
AVR and 96% for the ATS Medical
MVR. One should not choose to
compare some data while ignoring
other available data from the same
source.
Similarly, in an article by our group
published in The Annals of Thoracic
Surgery in 2005,4 the incidences of
all thromboembolism-related events
were 1.9%/patient-year for St Jude
Medical AVR and 2.8%/patient-year
for St Jude Medical MVR (St Jude
Medical, Inc, St Paul, Minn). Of these
thromboembolic events, 195 transient
ischemic attacks, 181 strokes, and
85 peripheral events occurred for
AVR, and 139 transient ischemic at-
tacks, 122 strokes, and 31 peripheral
events occurred for MVR. Thus
fewer than half the events cited by
Chan and colleagues1 were actuallyof Thoracic and Cardiovascular Surge‘‘major thromboembolic’’ events,
a further confusing point in their
comparison. The incidences for both
neurologic and peripheral events
were 1.04%/year for AVR and
1.49%/year for MVR.4 For neuro-
logic events only, incidences were
0.83%/year for AVR and 1.17%/
year for MVR. These numbers differ
from the comparison cited by Chan
and colleagues.1
As previously stated, the valve-
related mortality was not given in
Chan and colleagues’ Table 3,1 even
though it is easily found in the refer-
ence text (section Patient Survival).4
As shown in Table 3 and Figure 2 of
our group’s article,4 there were 230
aortic valve–related deaths during
21,741 patient-years of follow-up,
for a valve-related mortality of
1.05%/patient-year. With MVR, 130
valve-related deaths occurred during
10,441 patient-years of follow-up,
yielding a valve-related mortality of
1.24%/patient-year.
One must also note that in the defi-
nitions of postoperative management
by Chan and colleagues,1 an interna-
tional normalized ratio (INR) of 2.0
to 3.0 was used for anticoagulation.
In the 2005 article by our group,4
a prothrombin time of 1½ control
was used for the first 15 years of
follow-up, and a transition between
prothrombin and INRwas used during
the subsequent 5 years. Only in the
last 5 years of the study was INR
used exclusively. It is well known
that the measurement of prothrombin
time for anticoagulation of mechani-
cal heart valves is inferior to that
of INR, thus a direct comparison can-
not be made without noting the differ-
ent measurements of anticoagulant
management.
In summary, Table 3 of Chan and
colleagues1 misstates data from the
literature and adds confusion to the in-
terpretation of valve-related events.
This deficiency principally stems
from the absence of definitions and
the misuse of established criteria for
reporting events.ry c Volume 142, Number 3 719
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We thank Emery and Krogh for
their interest in our study describing
the intermediate-term outcomes after
aortic valve replacement (AVR) with
the On-X valve (On-X Life Technolo-
gies, Inc, Austin, Tex).1 We agree that
the reporting of clinical events related
to anticoagulation is important; how-
ever, the comments of Emery and
Krogh must be taken with the follow-
ing considerations.
In our study, clinical thromboem-
bolic and hemorrhagic events were
defined in accordance with current
guidelines.2 Although the current guide-
lines do not separate thromboembolic
events into major and minor categories,
major thromboembolic events have
been extensively reported by Jamieson
and colleagues.3 Our definition of the
termmajor thromboembolism incorpo-
rated all major events (cerebral and
peripheral, inclusive of reversible is-
chemic neurologic deficits).
With reference to Table 3 in our
original article,1 there was an error
on our part and also an error in the
comment by Emery and Krogh. The720 The Journal of Thoracic and Cmajor thromboembolic events rates
for the ATS prosthesis (ATS Medical,
Inc, Minneapolis, Minn) should be
0.7%/patient-year for AVR and 0.4%/
patient-year for mitral valve replace-
ment (MVR).4 The article about the
ATSmade no mention of reversible is-
chemic neurologic deficit events, and
it also did not document whether
such events were considered minor or
major. We mistakenly reported the
minor thromboembolic event rates,
which Emery and Krogh erroneously
stated as the total thromboembolic
event rates; however, the article gave
the total AVR thromboembolic event
rate for the ATS prosthesis as 2.6%/
patient-year and the total MVR throm-
boembolic event rate as 3.0%/patient-
year. For the St JudeMedical prosthesis
(St Jude Medical, Inc, St Paul, Minn),
the major neurologic and peripheral
thromboembolic event rates should
be 1.04%/patient-year for AVR and
1.49%/patient-year for MVR5; here,
we mistakenly reported total thrombo-
embolic events. There was, however,
no mention of reversible ischemic neu-
rologic deficit events in the thrombo-
embolic event categorization in that
article.
The valve-related mortalities were
neither reported nor calculated by
us in our Table 3.1 The AVR valve-
related mortalities were similar for
the On-X and ATS valves at 0.2%/
patient-year, whereas theMVR-related
mortality was higher for the ATS
valve at 0.4%/patient-year. The valve-
related mortalities for the St JudeMed-
ical valves were 1.05%/patient-year
for AVR and 1.24%/patient-year for
MVR.5
Emery and Krogh have correctly
identified the differences associated
with the measurement of prothrombin
time versus the international normal-
ized ratio.Wedid not discuss the impact
of using prothrombin time, because this
measurement is less commonly used to
monitor anticoagulation. Our study
involved a relatively recent cohort;
anticoagulation in all patients was
therefore managed by monitoring theardiovascular Surgery c September 201international normalized ratio, in ac-
cordance with the current recommen-
dations from the American Heart
Association and the American College
of Cardiology.6
We therefore believe that our
study provides insight regarding the
intermediate-term performance of the
On-X valve in a relatively large cohort
of patients.
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